FDA Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in…
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination…
Read More...
Read More...
